Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Cytokinetics Stock Tanked on Thursday

By Cory Renauer - Nov 7, 2019 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of a public debt offering didn't go over well with investors.

What happened

Shares of Cytokinetics ( CYTK 3.36% ), a clinical-stage biopharmaceutical company, tumbled after the company announced a $100 million convertible-debt offering. Concern about the potential dilution that will happen if the company can't repay its debt before the notes convert in 2026 pressured the stock, which fell by 19.4% as of 3:55 p.m. EST on Thursday.

So what 

After losing $91.1 million during the first nine months of 2019, Cytokinetics finished September with just $166 million in cash and short-term investments. Without any products to sell, the company's going to need more cash to support the continuing development of its clinical-stage pipeline.

Man in suit drawing a downward sloping chart.

Image source: Getty Images.

In partnership with Amgen, Cytokinetics is running the pivotal 8,200-patient Galactic study with its lead candidate, a heart-failure drug called omecamtiv mecarbil. Cytokinetics will also begin a midstage trial with a wholly owned new drug candidate, CK-274, before the end of 2019. 

Investors aren't too thrilled with the company's plan to raise up to $100 million through a convertible debt offering that matures in 2026 because the company's ability to repay that debt before it's converted into new shares is questionable, at best.

Now what

Cytokinetics already has a $45 million term loan that matures in 2023, and the potential approval of omecamtiv mecarbil won't help much. In 2017, the company monetized future royalties from Amgen for $90 million, and as of Sept. 30, that liability has swelled to $137.7 million.

The Galactic study isn't exactly a slam dunk, either. While omecamtiv mecarbil lowered heart tissue deformation in a midstage study, the pivotal Galactic trial is measuring the time to cardiovascular death or a heart-failure event.

If the Galactic study isn't a rousing success, Cytokinetics will be on the hook for a heap of convertible debt with no cash flow to pay for any of it. It's probably a good idea to steer clear of this risky biotech stock until it has significant amounts of revenue to work with.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cytokinetics, Incorporated Stock Quote
Cytokinetics, Incorporated
CYTK
$38.15 (3.36%) $1.24
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$201.17 (0.18%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.